Neulasta (pegfilgrastim)
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Neutropenia
Conditions
Neutropenia, Breast Cancer, Lung Cancer, Non-Hodgkin's Lymphoma, Ovarian Cancer
Trial Timeline
Jun 1, 2002 → Jan 1, 2005
NCT ID
NCT00277160About Neulasta (pegfilgrastim)
Neulasta (pegfilgrastim) is a approved stage product being developed by Amgen for Neutropenia. The current trial status is completed. This product is registered under clinical trial identifier NCT00277160. Target conditions include Neutropenia, Breast Cancer, Lung Cancer.
What happened to similar drugs?
7 of 17 similar drugs in Neutropenia were approved
Approved (7) Terminated (5) Active (8)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00277160 | Approved | Completed |
Competing Products
20 competing products in Neutropenia